Plasma biomarkers of Alzheimer´s disease in the continuum of dementia with Lewy bodies

  • Published on 06/05/2024
  •  Reading time: 4 min.

Patricia Diaz‐Galvan 1, Scott A. Przybelski 2, Alicia Algeciras‐Schimnich 1, Timothy G. Lesnick 2, Christopher G. Schwarz 1, Matthew L. Senjem 1, Jeffrey L. Gunter 1, Clifford R. Jack Jr. 1, Paul H Min 1, Manoj K. Jain 3, Toji Miyagawa 1, Leah K. Forsberg 1, Julie A. Fields 1, Rodolfo Savica 1, Jonathan Graff‐Radford 1, Vijay K Ramanan 1, David T. Jones 1, Hugo Botha 1, Erik K St. Louis 1, David S. Knopman 1, Neill R Graff‐Radford 3, Tanis J Ferman 3, Ronald C. Petersen 1, Val J. Lowe 4, Brad F. Boeve 1, Kejal Kantarci 4

1 Mayo Clinic, Rochester, MN USA
2 Mayo Clinic, Quantitative Health Sciences, Rochester, MN USA
3 Mayo Clinic, Jacksonville, FL USA
4 Mayo Clinic, Radiology, Rochester, MN USA


Background Patients with dementia with Lewy bodies (DLB) may have Alzheimer´s disease (AD) pathology. Plasma biomarkers of beta‐amyloid (Aβ), phosphorylated tau (pTau), and neurodegeneration are sensitive to AD neuropathologic changes in AD dementia. While these plasma biomarkers are well tested in the AD continuum, their performance for concomitant AD pathology in the DLB continuum is still unclear.
Method We included patients with isolated...


To continue reading this article in Full-Text...

* Access is totally free, without commitment or condition. Service exclusively reserved for healthcare professionals.

Peer-Reviewed Journals A-Z

Search | Advanced search

Get the latest news in Neurology

Receive our newsletter to stay up to date with the latest news in Neurology